Estropipate

Active ingredient: Estropipate

In short: Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause.

LabelPhysicians Total Care, Inc.
Label updatedMar 28, 2012

What is Estropipate used for?

Estropipate tablets are indicated in the:

Treatment of moderate to severe vasomotor symptoms associated

with the menopause.

Treatment of moderate to severe symptoms of vulval and vaginal

atrophy associated with the menopause. When prescribing solely for the treatment

of symptoms of vulvar and vaginal atrophy, topical vaginal products should be

considered.

Treatment of hypoestrogenism due to hypogonadism, castration or

primary ovarian failure.

Prevention of postmenopausal osteoporosis. When prescribing

solely for the prevention of postmenopausal osteoporosis, therapy should only be

considered for women at significant risk of osteoporosis and for whom

non-estrogen medications are not considered to be appropriate.

The mainstays for decreasing the risk of postmenopausal osteoporosis are

weight-bearing exercise, adequate calcium and vitamin D intake, and when

indicated, pharmacologic therapy. Postmenopausal women require an average of

1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium

supplementation may be helpful for women with suboptimal dietary intake. Vitamin

D supplementation of 400-800 IU/day may also be required to ensure adequate

daily intake in postmenopausal women.

âš  Boxed warning (FDA's strongest warning)

Close clinical surveillance of all women taking estrogens is

important. Adequate diagnostic measures, including endometrial sampling when

indicated, should be undertaken to rule out malignancy in all cases of

undiagnosed persistent or recurring abnormal vaginal bleeding. There is no

evidence that the use of “natural” estrogens result in a different endometrial

risk profile than “synthetic” estrogens at equivalent estrogen doses.

Estrogens with and without progestins should not be used for the

prevention of cardiovascular disease.

The Women’s Health Initiative (WHI) study reported increased risks of

myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and

deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5

years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with

medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo.

The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI,

reported increased risk of developing probable dementia in postmenopausal women

65 years of age or older during 4 years of treatment with oral conjugated

estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown

whether this finding applies to younger postmenopausal women or to women taking

estrogen alone therapy.

Other doses of conjugated estrogens with medroxyprogesterone

acetate, and other combinations and dosage forms of estrogens and progestins

were not studied in the WHI clinical trials and, in the absence of comparable

data, these risks should be assumed to be similar. …

Estropipate dosage

When estrogen is prescribed for a woman with a uterus, progestin

should also be initiated to reduce the risk of endometrial cancer. A woman

without a uterus does not need progestin. Use of estrogen, alone or in

combination with a progestin, should be with the lowest effective dose and for

the shortest duration consistent with treatment goals and risks for the

individual woman. Patients should be reevaluated periodically as clinically

appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is

still necessary For women who have a uterus, adequate diagnostic measures,

such as endometrial sampling, when indicated, should be undertaken to rule out

malignancy in cases of undiagnosed persistent or recurring abnormal vaginal

bleeding.

For treatment of moderate to severe vasomotor symptoms, vulval

and vaginal atrophy associated with the menopause, the lowest dose and regimen

that will control symptoms should be chosen and medication should be

discontinued as promptly as possible. Attempts to discontinue or taper

medication should be made at 3month to 6-month intervals. Usual dosage

ranges:

Vasomotor symptoms—One estropipate 0.75

mg tablet to two estropipate 3 mg tablets per day. The lowest dose that will

control symptoms should be chosen. If the patient has not menstruated within the

last two months or more, cyclic administration is started arbitrarily. If the

patient is menstruating, cyclic administration is started on day 5 of

bleeding.

Vulval and vaginal atrophy—One

estropipate 0.75 mg tablet to two estropipate 3 mg tablets daily, depending upon

the tissue response of the individual patient. The lowest dose that will control

symptoms should be chosen. Administer cyclically.

For treatment of female hypoestrogenism due to hypogonadism,

castration, or primary ovarian failure. Usual dosage ranges:

Female hypogonadism—A daily dose of one estropipate 1.5 mg

tablet to three estropipate 3 mg tablets may be given for the first three weeks

of a theoretical cycle, followed by a rest period of eight to ten days. The

lowest dose that will control symptoms should be chosen. If bleeding does not

occur by the end of this period, the same dosage schedule is repeated. The

number of courses of estrogen therapy necessary to produce bleeding may vary

depending on the responsiveness of the endometrium. If satisfactory withdrawal

bleeding does not occur, an oral progestogen may be given in addition to

estrogen during the third week of the cycle.

Female

castration or primary ovarian failure—A daily dose of one estropipate 1.5

mg tablet to three estropipate 3 mg tablets may be given for the first three

weeks of a theoretical cycle, followed by a rest period of eight to ten days. …

How to take Estropipate — instructions & advice from the label

Estropipate Tablets USP

Read this PATIENT INFORMATION before you start taking estropipate tablets and

read what you get each time you refill estropipate tablets. There may be new

information. This information does not take the place of talking to your health

care provider about your medical condition or your treatment.

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT

ESTROPIPATE (AN ESTROGEN HORMONE)?

• Estrogens increase the chances of getting cancer of the uterus.Report any unusual vaginal bleeding right away while you are taking estrogens.

Vaginal bleeding after menopause may be a warning sign of cancer of the uterine

(womb). Your health care provider should check any unusual vaginal bleeding to

find out the cause.

• Do not use estrogens with or without progestins to prevent heart disease,

heart attacks or strokes.Using estrogens with or without progestins may increase your chances of getting

heart attacks, strokes, breast cancer and blood clots. You and your health care

provider should talk regularly about whether you still need treatment with

estropipate tablets.

What is estropipate?

Estropipate is a medicine that contains estrogen hormones. …

Warnings & precautions

Do not take this medicine if: Estropipate tablets should not be used in women with any of the

following conditions:

Undiagnosed abnormal genital bleeding.

Known, suspected, or history of cancer of the breast.

Known or suspected estrogen-dependent neoplasia.

Active deep vein thrombosis, pulmonary embolism or history of

these conditions.

Active or recent (e.g., within the past year) arterial

thromboembolic disease (e.g., stroke, myocardial infarction).

Liver dysfunction or disease.

Estropipate tablets should not be used in patients with known

hypersensitivity to its ingredients.

Known or suspected pregnancy. There is no indication for

estropipate tablets in pregnancy.

There appears to be little or no increased risk of birth defects in children

born to women who have used estrogens and progestins from oral contraceptives

inadvertently during early pregnancy.

Enter section text here

Studies of the addition of a progestin for 10 or more days of a

cycle of estrogen administration, or daily with estrogen in a continuous

regimen, have reported a lowered incidence of endometrial hyperplasia than would

be induced by estrogen treatment alone. Endometrial hyperplasia may be a

precursor to endometrial cancer.

There are, however, possible risks that may be associated with the use of

progestins with estrogens compared to estrogen-alone regimens. These include a

possible increased risk of breast cancer, adverse effects on lipoprotein

metabolism (e.g., lowering HDL, raising LDL) and impairment of glucose

tolerance.

In a small number of case reports, substantial increases in blood

pressure have been attributed to idiosyncratic reactions to estrogens. In a

large, randomized, placebo-controlled clinical trial, a generalized effect of

estrogens on blood pressure was not seen. Blood pressure should be monitored at

regular intervals with estrogen use. …

Estropipate side effects

See

BOXED

WARNINGS

,

WARNINGS

and

PRECAUTIONS

.

The following additional adverse reactions have been reported with estrogens

and/or progestin therapy.

Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow;

breakthrough bleeding; spotting; dysmenorrhea; increase in size of uterine

leiomyomata; vaginitis; including vaginal candidiasis; change in amount of

cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial

hyperplasia; endometrial cancer.

Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic

breast changes; breast cancer.

Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis;

myocardial infarction; stroke; increase in blood pressure.

Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased

incidence of gallbladder disease; pancreatitis; enlargement of hepatic

hemangiomas.

Chloasma or melasma that may persist when drug is discontinued; erythema

multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair;

hirsutism; pruritus, rash.

Retinal vascular thrombosis; steepening of corneal curvature; intolerance to

contact lenses.

Headache, migraine, dizziness; mental depression; chorea; nervousness; mood

disturbances; irritability; exacerbation of epilepsy; dementia. …

About this medicine

Estropipate (formerly piperazine estrone sulfate), is a natural estrogenic

substance prepared from purified crystalline estrone, solubilized as the sulfate

and stabilized with piperazine. It is appreciably soluble in water and has

almost no odor or taste — properties which are ideally suited for oral

administration. The amount of piperazine in estropipate is not sufficient to

exert a pharmacological action. Its addition ensures solubility, stability, and

uniform potency of the estrone sulfate. Chemically estropipate, molecular

weight: 436.56, is represented by estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-,

compound with piperazine (1:1). The structural formula may be represented as

follows:

C18H22O5S.C4H10N2 | M.W.=436.56

Estropipate is available as tablets for oral administration containing either

0.75 mg, 1.5 mg, 3 mg, or 6 mg estropipate (calculated as sodium estrone sulfate

0.625 mg, 1.25 mg, 2.5 mg and 5 mg, respectively). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 03cdbf5b-b572-448f-80e9-b3e812959901. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone